From - Wed Jan  9 13:27:12 2008
Received: from mail.mdanderson.org (mail.mdanderson.org [143.111.251.38])
        by wotan.mdacc.tmc.edu (8.13.6/) with ESMTP id m04EavJF097535
        for <kabagg@wotan.mdacc.tmc.edu>; Fri, 4 Jan 2008 08:36:57 -0600 (CST)
Received: from ([171.66.124.133])
	by mdairnmail2.mdacc.tmc.edu with ESMTP  id KP-BRCRK.138606979;
	Fri, 04 Jan 2008 08:36:35 -0600
Received: from madcap.stanford.edu (madcap.Stanford.EDU [171.66.121.176])
	by marz.stanford.edu (Postfix) with ESMTP id AACF22DEB89;
	Fri,  4 Jan 2008 06:36:36 -0800 (PST)
Received: from madcap.stanford.edu (localhost [127.0.0.1])
	by madcap.stanford.edu (Postfix) with ESMTP id 86373CC8;
	Fri,  4 Jan 2008 06:36:35 -0800 (PST)
Message-ID: <27992909.1199457395538.JavaMail.benchpress@highwire.org>
From: gunne@asco.org
To: Keith A Baggerly <kabagg@mdanderson.org>, crboucha@mdanderson.org
Subject: Decision/Correspondence - JCO/2007/151985
Mime-Version: 1.0
Content-Type: text/plain; charset=ISO8859-1
Content-Transfer-Encoding: quoted-printable
Date: Fri,  4 Jan 2008 06:36:35 -0800 (PST)
X-esp: ESP<2>=
	SHA:<0> 
	UHA:<9> 
	ISC:<0> 
	BAYES:<-1> 
	SenderID:<0> 
	DKIM:<1> 
	TS:<-7> 
	SIG:<dgWhK_11AAji9fyIeqSBLXJoou8sx7jMP5PRWAXLC_XXAAAAAAAAAAAAAAAA
	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	AAAAAAAAAAAAAAAAAAAUF5Zzu2NSKKxmXLr_lCRkL1LEm5ciPT3GQLnGNX6H
	bLWXwlvf5aCToUiGqNWip-vAkAlKNzHcV0ru--bRCrAgujSNA>
	TRU_html_image_spam: <0>
	TRU_embedded_image_spam: <0>
	TRU_spam2: <0>
	TRU_marketing_spam: <0>
	TRU_urllinks: <0>
	TRU_spam1: <0>
	TRU_stock_spam: <0>
	TRU_adult_spam: <0>
	TRU_scam_spam: <0>
	TRU_phish_spam: <0>
	TRU_medical_spam: <0>
	TRU_charsets: <0>
	TRU_money_spam: <0>
	TRU_profanity_spam: <0>
	TRU_misc_spam: <0>
	TRU_watch_spam: <0>
	TRU_playsites: <0>
	URL Real-Time Signatures: <0>
	TRU_lotto_spam: <0>
	TRU_legal_spam: <0>
	TRU_freehosting: <0>
X-Mozilla-Status: 8001
X-Mozilla-Status2: 00000000
X-UIDL: \$["!k:K!!)9*#!]YR"!

Dear Dr. Baggerly:

We have reviewed your correspondence, titled =93Pharmacogenomic Strategies =
May Not
Provide a Rational Approach to the Treatment of Cisplatin-Resistant Patient=
s
with Advanced Lung Cancer.=94  I regret to inform you that we cannot accept=
 your
correspondence for publication.

Thank you for giving us the opportunity to consider your correspondence for=
 the
Journal of Clinical Oncology.

Sincerely,

Daniel G. Haller, MD
Editor-in-Chief
Journal of Clinical Oncology




RC